B
BiotechEdge
Start Free Trial

Biotech Catalyst Calendar

Upcoming PDUFA dates, Phase 2/3 readouts, and advisory committee meetings sourced from ClinicalTrials.gov. Updated weekly.

1869 active catalysts tracked106 Phase 3 Readout193 Phase 2 Readout1 PDUFA

Upcoming Events

March 2026

NBIXPhase 3 ReadoutValbenazine — Chorea, Huntington

Q1 2026

AMGNPhase 2 ReadoutBlinatumomab — Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive

Q1 2026

UTHRPhase 2 ReadoutIbrutinib 560 mg — Mantle Cell Lymphoma

Mar 31, 2026

Today

NBIXPhase 2 ReadoutNbi-921352 — SCN8A Developmental and Epileptic Encephalopathy Syndrome

Q1 2026

NTRAPhase 2 ReadoutTrastuzumab deruxtecan — Gastrooesophageal Cancer

Mar 31, 2026

Today

UTHRPhase 2 Readoutipatasertib — Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic

Q1 2026

INCYPhase 2 ReadoutRuxolitinib Topical Cream — Exanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy

Q1 2026

INCYPhase 2 ReadoutDoxorubicin — Resectable Sarcoma

Q1 2026

INCYPhase 2 ReadoutRuxolitinib — Hodgkin Lymphoma

Q1 2026

UTHRPhase 2 ReadoutIodine-124 — Thyroid Cancer

Mar 31, 2026

Today

UTHRPhase 2 Readout177lu-Psma-617 — Metastatic Hormone Naive Prostate Cancer

Q1 2026

IMVTPhase 3 ReadoutBatoclimab — Thyroid Eye Disease

Q1 2026

CLDXPhase 2 ReadoutHuman CMV pp65-LAMP m RNA-pulsed autologous DCs — Glioblastoma

Q1 2026

AGIOPhase 2 ReadoutAg-120 — Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3

Q1 2026

MDGLPhase 3 ReadoutResmetirom — Non-Alcoholic Fatty Liver Disease

Q1 2026

ABBVPhase 3 ReadoutVenetoclax — Myelodysplastic Syndrome (MDS)

Q1 2026

AAVXFPhase 2 ReadoutAbx464 — Ulcerative Colitis

Q1 2026

AGIOPhase 2 ReadoutTebapivat — Myelodysplastic Syndromes

Q1 2026

EXELPhase 2 ReadoutCabozantinib — High Grade Neuroendocrine Neoplasms

Mar 31, 2026

Today

VIRPhase 2 ReadoutVir-2218 — Hepatitis B, Chronic

Q1 2026

AMLXPhase 3 ReadoutAvexitide — Post Bariatric Hypoglycemia

Q1 2026

ADCTPhase 3 ReadoutLoncastuximab Tesirine — Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

Mar 31, 2026

Today

IVVDPhase 3 ReadoutVyd2311-Sd — Covid-19

Q1 2026

PFEPhase 2 ReadoutTalazoparib — Breast Cancer

Q1 2026

SVAPhase 3 ReadoutParticipants will receive one dose of vaccine (0.5 m L) of Sinovac QIV — Influenza

Q1 2026

PFEPhase 2 ReadoutDacomitinib — Nsclc Stage Iiib, Nsclc Stage Iiic, Nsclc Stage Iv

Mar 31, 2026

Today

PFEPhase 2 ReadoutTisotumab Vedotin — Cervical Cancer

Mar 31, 2026

Today

April 2026

AMGNPhase 2 ReadoutAmg 193 — MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors

Apr 1, 2026

Tomorrow

REGNPhase 2 ReadoutSarilumab SAR153191 (REGN88) — Juvenile Idiopathic Arthritis

Apr 1, 2026

Tomorrow

INCYPhase 3 ReadoutTafasitamab — Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma

Apr 1, 2026

Tomorrow

PTGXPhase 3 ReadoutOpen-label rusfertide — Polycythemia Vera

Apr 1, 2026

Tomorrow

AMLXPhase 3 ReadoutAmx0035 — Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases

Apr 1, 2026

Tomorrow

PFEPhase 2 ReadoutAxitinib — Metastatic Renal Cell Carcinoma

Apr 1, 2026

Tomorrow

PFEPhase 3 Readouttucatinib — Colorectal Neoplasms

Apr 3, 2026

3d

PFEPhase 2 Readoutmaplirpacept (PF-07901801) — Diffuse Large B-Cell Lymphoma

Apr 6, 2026

6d

EXELPhase 2 ReadoutCabozantinib — Castration-resistant Prostate Cancer, Metastatic Cancer

Apr 12, 2026

12d

INCYPhase 2 Readoutretifanlimab — Endometrial Cancer

Apr 14, 2026

14d

PFEPhase 2 ReadoutMet233 — Obesity and Overweight

Apr 15, 2026

15d

REGNPhase 2 ReadoutFianlimab — Resectable Non-small Cell Lung Cancer

Apr 17, 2026

17d

PFEPhase 3 ReadoutDexmedetomidine — Delirium, Critical Illness, Sedation Complication

Apr 17, 2026

17d

PFEPhase 3 ReadoutElranatamab — Multiple Myeloma

Apr 27, 2026

27d

OCULPhase 3 ReadoutOTX-TKI (axitinib implant) — Neovascular Age-Related Macular Degeneration

Apr 29, 2026

29d

NBIXPhase 3 ReadoutValbenazine — Chorea, Huntington

Q2 2026

BIIBPhase 2 ReadoutBiib122 225 Mg — Parkinson Disease

Apr 30, 2026

30d

REGNPhase 2 ReadoutCemiplimab — Colon Cancer

Apr 30, 2026

30d

IONSPhase 3 ReadoutEplontersen — Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Q2 2026

UTHRPhase 2 Readoutcyclophosphamide — Malignant Pleural Disease, Mesothelioma, Metastases

Apr 30, 2026

30d

DNLIPhase 2 ReadoutBiib122 225 Mg — Parkinson Disease

Apr 30, 2026

30d

RCUSPhase 2 ReadoutZimberelimab — Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer

Apr 30, 2026

30d

CNTAPhase 2 ReadoutOrx750 — Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

Apr 30, 2026

30d

RCUSPhase 2 ReadoutAtezolizumab — Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer

Apr 30, 2026

30d

JAZZPhase 2 ReadoutNabiximols — Glioblastoma, Brain Tumor, Cannabis

Q2 2026

AAVXFPhase 3 ReadoutAbx464 — Ulcerative Colitis

Q2 2026

BNTXPhase 2 ReadoutDb-1303/Bnt323 — HER2-positive Advanced Solid Tumor

Q2 2026

OCSAWPhase 3 ReadoutDexamethasone ophthalmic suspension (OCS-01) — Diabetic Macular Edema

Q2 2026

PFEPhase 2 ReadoutTrastuzumab — Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer

Q2 2026

ORKAPhase 2 ReadoutORKA-001 Induction Dose — Plaque Psoriasis

Q2 2026

PFEPhase 2 Readoutvepdegestrant — Breast Cancer

Apr 30, 2026

30d

VTGNPhase 2 ReadoutFasedienol Nasal Spray - Placebo Nasal Spray — Social Anxiety Disorder

Q2 2026

VTGNPhase 3 ReadoutFasedienol Nasal Spray — Social Anxiety Disorder (SAD)

Q2 2026

May 2026

INCYPhase 2 ReadoutCyclophosphamide — B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

May 1, 2026

ADCTPhase 2 ReadoutLoncastuximab Tesirine — Waldenstrom Macroglobulinemia

May 1, 2026

RCKTPhase 2 ReadoutRp-L102 — Fanconi Anemia Complementation Group A

May 5, 2026

BNTXPhase 3 ReadoutBNT162b2 (2025/2026 recommended SARS-Co V-2 strain) — Covid-19, Sars-Cov-2 Infection

May 5, 2026

PFEPhase 3 ReadoutBNT162b2 (2025/2026 recommended SARS-Co V-2 strain) — Covid-19, Sars-Cov-2 Infection

May 5, 2026

INCYPhase 2 ReadoutInc.b177054 — Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

May 8, 2026

SVAPhase 3 ReadoutSinovac PCV13 — Pneumococcal Infectious Disease

May 12, 2026

BIIBPhase 2 ReadoutBiib080 — Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

May 14, 2026

REGNPhase 2 ReadoutDupilumab — Colitis Ulcerative

May 15, 2026

SMMTPhase 2 ReadoutAk112 — Metastatic Colorectal Cancer

May 15, 2026

REGNPhase 2 ReadoutTrevogrumab-Part A — Obesity

May 18, 2026

DSGNPhase 3 ReadoutAbiraterone - Usual — Prostate Cancer

May 18, 2026

AMGNPhase 3 ReadoutRomiplostim — Chemotherapy-induced Thrombocytopenia

May 20, 2026

PFEPhase 2 ReadoutMultivalent Pneumococcal Vaccine - Formulation 1 — Pneumococcal Disease

May 23, 2026

UTHRPhase 2 ReadoutR F1v-1018 — Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

May 29, 2026

AMGNPhase 2 Readoutsotorasib — KRAS p.G12C Mutant Advanced Solid Tumors

May 30, 2026

INCYPhase 2 ReadoutAxatilimab — Hodgkin Lymphoma

Q2 2026

ABBVPhase 3 ReadoutPlacebo for Risankizumab SC — Crohn's Disease

Q2 2026

UTHRPhase 3 ReadoutUnited Therapeutics Corporation — Spinal Cord Injuries

May 31, 2026

CRSPPhase 3 ReadoutCtx001 — Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance

May 31, 2026

EXELPhase 3 ReadoutXl092 — Colorectal Cancer

Q2 2026

ARWRPhase 3 ReadoutPlozasiran Injection — Hypertriglyceridemia

Q2 2026

TNGXPhase 2 ReadoutTng462 — Locally Advanced Solid Tumor

Q2 2026

AGIOPhase 2 ReadoutTebapivat — Sickle Cell Disease

Q2 2026

BNTXPhase 3 ReadoutDb-1303/Bnt323 — Metastatic Breast Cancer

Q2 2026

ARWRPhase 2 ReadoutAro-Inhbe — Obesity

Q2 2026

GHPhase 2 ReadoutOsimertinib — Metastatic Non-small Cell Lung Cancer

Q2 2026

GLUEPhase 2 ReadoutOral MRT-2359 — NSCLC, SCLC, High Grade Neuroendocrine Cancer

Q2 2026

EVMNPhase 2 ReadoutEvo756 — Chronic Spontaneous Urticaria

Q2 2026

HCATPhase 2 ReadoutMhs-1031 — Gastroesophageal Reflux

Q2 2026

NPCEPhase 2 ReadoutNeuro Pace Inc. — Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable

May 31, 2026

SVAPhase 2 ReadoutLow-dose experimental vaccine — Herpes Zoster, m RNA Vaccine

May 31, 2026

PFEPhase 2 Readoutdisitamab vedotin — Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms

May 31, 2026

June 2026

REGNPhase 2 ReadoutRegn9933 — Venous Thromboembolism

Jun 1, 2026

UTHRPhase 2 ReadoutClemastine Fumarate — Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive

Jun 1, 2026

UTHRPhase 2 ReadoutKetamine — Multiple Sclerosis Fatigue

Jun 1, 2026

EXELPhase 2 ReadoutNivolumab — Hepatocellular Carcinoma, HCC

Jun 1, 2026

BSXPhase 2 ReadoutBoston Scientific Corp — Stage I Renal Cell Cancer, Stage II Renal Cell Cancer

Jun 1, 2026

PFEPhase 2 ReadoutEncorafenib — Metastatic Colorectal Cancer

Jun 1, 2026

BIIBPhase 3 ReadoutBiogen Inc. — Choroideremia, X-Linked Retinitis Pigmentosa

Jun 4, 2026

REGNPhase 3 ReadoutDupilumab — Lichen Simplex Chronicus

Jun 8, 2026

INCYPhase 2 Readoutpovorcitinib — Moderate to Severe Asthma

Jun 15, 2026

SVAPhase 2 ReadoutOral hexavalent reassortant rotavirus attenuated live vaccine — Rotavirus Gastroenteritis

Jun 15, 2026

BNTXPhase 3 ReadoutBivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose — SARS-Co V-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

Jun 16, 2026

PFEPhase 3 ReadoutBivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose — SARS-Co V-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

Jun 16, 2026

INCYPhase 2 ReadoutItacitinib — Diffuse Large B Cell Lymphoma

Jun 20, 2026

EXELPhase 2 ReadoutCabozantinib — Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma

Jun 20, 2026

INCYPhase 2 Readoutitacitinib — Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease

Jun 22, 2026

IDYAPhase 2 ReadoutGsk4418959 — Neoplasms, Colorectal, Solid Tumor, Colon Cancer

Jun 22, 2026

WVEPhase 2 ReadoutWve-N531 — Duchenne Muscular Dystrophy

Jun 27, 2026

CELCPhase 3 ReadoutGedatolisib — Breast Cancer

Jun 30, 2026

AMGNPhase 2 ReadoutDaratumumab — Myeloma, Multiple Myeloma

Q2 2026

AMGNPhase 2 Readoutavutometinib and sotorasib — Non Small Cell Lung Cancer, KRAS Activating Mutation

Q2 2026

AMGNPhase 2 ReadoutBlinatumomab 9ug — Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia

Jun 30, 2026

AMGNPhase 3 ReadoutSotorasib — Non-Small Cell Lung Cancer (NSCLC)

Jun 30, 2026

AMGNPhase 2 ReadoutAmg 193 — Advanced MTAP-null Solid Tumors

Jun 30, 2026

UTHRPhase 2 ReadoutLinaclotide — Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8

Jun 30, 2026

UTHRPhase 3 ReadoutInhaled Treprostinil — Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

Q2 2026

UTHRPhase 3 ReadoutUb-421 — HIV-1 Infection

Jun 30, 2026

INCYPhase 2 ReadoutInc.mga00012 — Well-differentiated/Dedifferentiated Liposarcoma

Q2 2026

IONSPhase 3 ReadoutIon363 — Amyotrophic Lateral Sclerosis

Q2 2026

UTHRPhase 2 ReadoutDexamethasone — Voice Change, Hypocalcemia

Jun 30, 2026

UTHRPhase 2 ReadoutEnzalutamide 40mg — Metastatic Castration-Resistant Prostate Cancer (m CRPC)

Jun 30, 2026

UTHRPhase 3 ReadoutUnited Therapeutics Corporation — Autism Spectrum Disorder

Q2 2026

TVTXPhase 2 ReadoutPegtibatinase — Homocystinuria

Q2 2026

UTHRPhase 3 ReadoutLopinavir-Ritonavir — Severe Acute Respiratory Syndrome

Jun 30, 2026

FOLDPhase 3 ReadoutCipaglucosidase Alfa — Pompe Disease (Late-onset)

Q2 2026

VSTMPhase 2 Readoutavutometinib and sotorasib — Non Small Cell Lung Cancer, KRAS Activating Mutation

Q2 2026

RVMDPhase 3 ReadoutRmc-6236 — Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Q2 2026

PTCTPhase 3 ReadoutPtc923 — Phenylketonuria

Jun 30, 2026

CLDXPhase 2 Readoutbarzolvolimab — Prurigo Nodularis

Q2 2026

CMPSPhase 3 ReadoutPsilocybin — Major Depressive Disorder

Jun 30, 2026

EXELPhase 2 ReadoutCabozantinib — Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer

Q2 2026

ARWRPhase 3 ReadoutPlozasiran Injection — Severe Hypertriglyceridemia

Q2 2026

ALKSPhase 2 ReadoutAlks 2680 — Idiopathic Hypersomnia

Q2 2026

MIRMPhase 2 ReadoutVolixibat — Primary Sclerosing Cholangitis

Q2 2026

FDMTPhase 2 Readout4d-310 — Fabry Disease

Q2 2026

ARWRPhase 2 ReadoutAro-Dimerpa — Hyperlipidemia; Mixed

Q2 2026

RCUSPhase 3 ReadoutDomvanalimab — Advanced Upper Gastrointestinal Tract Adenocarcinoma

Q2 2026

RGNXPhase 2 ReadoutTopical Steroid — Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)

Q2 2026

FDMTPhase 2 Readout4D-125 IVT Injection — X-Linked Retinitis Pigmentosa

Q2 2026

JAZZPhase 2 ReadoutPaclitaxel — Gastroesophageal Adenocarcinoma

Jun 30, 2026

AGIOPhase 2 ReadoutMitapivat — Anemia

Jun 30, 2026

COGTPhase 2 ReadoutBezuclastinib in combination with sunitinib — Gastrointestinal Stromal Tumors, GIST

Q2 2026

EWTXPhase 2 ReadoutEdg-7500 — Hypertrophic Cardiomyopathy

Q2 2026

PRAXPhase 3 Readout1mg elsunersen — Epileptic Encephalopathy, SCN2A Encephalopathy

Q2 2026

PFEPhase 2 ReadoutPalbociclib — Breast Cancer Stage II, Breast Cancer Stage III

Jun 30, 2026

CGONPhase 2 ReadoutIvaltinostat — Metastatic Pancreatic Adenocarcinoma

Q2 2026

CGONPhase 3 ReadoutCretostimogene Grenadenorepvec — Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer

Q2 2026

SYREPhase 2 ReadoutSpy001 — Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

Q2 2026

ENGNWPhase 2 ReadoutEG-70 (phase 1) — Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Jun 30, 2026

OCSAWPhase 2 ReadoutOcs-01 — Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative

Q2 2026

KALVPhase 3 ReadoutKVD900 600 mg — Hereditary Angioedema

Jun 30, 2026

BSXPhase 2 ReadoutPembrolizumab — Breast Cancer

Q2 2026

OLMAPhase 3 ReadoutPalazestrant — Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

Jun 30, 2026

SPRYPhase 2 ReadoutPlacebo — Urticaria Chronic

Q2 2026

PFEPhase 2 Readoutanastrozole — Female Breast Carcinoma, Breast Cancer

Jun 30, 2026

PFEPhase 2 ReadoutAbrocitinib 200 MG Oral Tablet — Diabetes Mellitus, Type 1

Jun 30, 2026

ZBIOPhase 3 ReadoutObexelimab — Warm Autoimmune Hemolytic Anemia

Jun 30, 2026

ZBIOPhase 2 ReadoutObexelimab — Systemic Lupus Erythematosus

Q2 2026

PFEPhase 3 Readoutdisitamab vedotin — Urothelial Carcinoma

Jun 30, 2026

PFEPhase 2 ReadoutTalazoparib — Breast Cancer

Q2 2026

ACIUPhase 2 ReadoutPlacebo — Amyloid Plaque, Beta-Amyloid, DSAD

Q2 2026

PFEPhase 2 ReadoutAnti-OX40 Antibody PF-04518600 — Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer

Jun 30, 2026

QTTBPhase 2 Readoutbempikibart (ADX-914) — Alopecia Areata

Q2 2026

July 2026

UTHRPhase 2 Readoutc P12 — Thermal Burns

Jul 1, 2026

SMMTPhase 2 ReadoutIvonescimab — Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer

Jul 1, 2026

RCUSPhase 2 ReadoutZimberelimab — Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma

Jul 1, 2026

ALMSPhase 2 ReadoutEsk-001 — Sle

Jul 1, 2026

INCYPhase 2 ReadoutInc.a034176 — Chronic Graft-versus-host-disease

Jul 3, 2026

REGNPhase 2 ReadoutOdronextamab — B-cell Non-Hodgkin Lymphoma (B-NHL)

Jul 6, 2026

INCYPhase 3 ReadoutRuxolitinib — Atopic Dermatitis

Jul 13, 2026

PFEPhase 3 ReadoutPf-06821497 — Metastatic Castrate Resistant Prostate Cancer (m CRPC)

Jul 13, 2026

AMGNPhase 3 ReadoutTezepelumab — Eosinophilic Esophagitis

Jul 14, 2026

REGNPhase 3 Readoutmibavademab — Generalized Lipodystrophy

Jul 14, 2026

CELCPDUFAgedatolisib — HR+/HER2- breast cancer

Jul 17, 2026

INCYPhase 2 ReadoutInc.b099280 — Advanced Solid Tumor

Jul 22, 2026

CERSPhase 2 ReadoutCerus Corporation — Healthy Subjects

Jul 30, 2026

PFEPhase 3 Readoutnirmatrelvir — Covid-19

Jul 30, 2026

UTHRPhase 2 ReadoutRecombinant human growth hormone — Gulf War Syndrome, Adult Growth Hormone Deficiency

Q3 2026

ARGXPhase 2 ReadoutEfgartigimod — Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa

Q3 2026

INCYPhase 2 ReadoutPemigatinib — Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation

Q3 2026

BIIBPhase 3 ReadoutNusinersen — Muscular Atrophy, Spinal

Jul 31, 2026

UTHRPhase 2 ReadoutTestosterone cypionate — Castration Resistant Metastatic Prostate Cancer

Q3 2026

UTHRPhase 3 ReadoutTranexamic Acid — Spinal Injuries, Spinal Deformity

Q3 2026

RAREPhase 3 ReadoutGtx-102 — Angelman Syndrome

Q3 2026

UTHRPhase 2 ReadoutUnited Therapeutics Corporation — Post-Concussion Syndrome, Concussion, Brain, Mild Traumatic Brain Injury

Q3 2026

UTHRPhase 3 ReadoutTobramycin Injection — Wound Infection, Fractures, Open, Surgical Site Infection

Q3 2026

UTHRPhase 2 ReadoutInfusion of 5 mg/kg Infliximab — Acute Pancreatitis

Jul 31, 2026

EXELPhase 2 ReadoutCabozantinib — Non-Small Cell Lung Cancer

Q3 2026

JAZZPhase 3 ReadoutZanidatamab — Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

Jul 31, 2026

BEIGFPhase 3 ReadoutZanidatamab — Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

Jul 31, 2026

GPCRPhase 2 ReadoutAleniglipron or Placebo — Obesity, Overweight, or Chronic Weight Management

Q3 2026

BNTXPhase 3 ReadoutBNT162b2 Vaccine — Covid-19, Sars-Cov-2 Infection

Jul 31, 2026

ARWRPhase 2 ReadoutAro-Alk7 — Obesity, Diabetes Mellitus, Type 2

Q3 2026

CERSPhase 3 ReadoutCerus Corporation — Anemia

Jul 31, 2026

BNTXPhase 3 ReadoutBNT162b2 (2025/2026 formulation) — Covid-19, Sars-Cov-2 Infection

Jul 31, 2026

BEIGFPhase 3 ReadoutTislelizumab — Advanced Malignancies

Q3 2026

JAZZPhase 2 ReadoutLurbinectedin — Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma

Q3 2026

PRAXPhase 3 Readout1.0mg/kg/day PRAX-562 — Developmental and Epileptic Encephalopathy 1

Q3 2026

EVMNPhase 2 ReadoutEvo756 — Atoptic Dermatitis

Q3 2026

SIONPhase 2 ReadoutSion-719 — Cystic Fibrosis (CF)

Q3 2026

PFEPhase 3 ReadoutBNT162b2 (2025/2026 formulation) — Covid-19, Sars-Cov-2 Infection

Jul 31, 2026

PFEPhase 3 ReadoutBNT162b2 Vaccine — Covid-19, Sars-Cov-2 Infection

Jul 31, 2026

August 2026

UTHRPhase 2 ReadoutUnited Therapeutics Corporation — Amputation

Aug 1, 2026

UTHRPhase 3 ReadoutBupivacaine — Postoperative Pain

Aug 1, 2026

PFEPhase 2 ReadoutElranatamab — Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma

Aug 1, 2026

TMOPhase 3 ReadoutIV Tulisokibart — Ulcerative Colitis

Aug 1, 2026

AMGNPhase 3 ReadoutApremilast — Plaque Psoriasis

Aug 6, 2026

REGNPhase 2 ReadoutItepekimab (SAR440340) — Chronic Rhinosinusitis Without Nasal Polyps

Aug 7, 2026

INCYPhase 3 ReadoutRuxolitinib Cream — Non Segmental Vitiligo

Aug 10, 2026

TMOPhase 3 ReadoutNexium 20mg — Erosive Esophagitis

Aug 14, 2026

UTHRPhase 3 ReadoutRifampicin — Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions

Aug 15, 2026

UTHRPhase 2 ReadoutP Umvc3-Igfbp2-Her2-Igf1r Plasmid Dna Vaccine — Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8

Aug 15, 2026

PMVPPhase 2 Readoutrezatapopt — Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer

Aug 15, 2026

ARGXPhase 2 Readoutargenx SE — Systemic Sclerosis (SSc)

Aug 17, 2026

PFEPhase 2 ReadoutAtm-Avi — Gram-negative Bacterial Infections

Aug 17, 2026

AMGNPhase 3 ReadoutDazodalibep — Sjogren's Syndrome

Aug 19, 2026

REGNPhase 2 ReadoutRegn7075 — Advanced Solid Tumors

Aug 19, 2026

PFEPhase 2 ReadoutIpilimumab — Melanoma

Aug 20, 2026

PFEPhase 2 ReadoutPF-07220060 + PF-07104091 combination dose escalation — Breast Cancer, Solid Tumors

Aug 23, 2026

PFEPhase 3 ReadoutElranatamab — Multiple Myeloma

Aug 30, 2026

UTHRPhase 2 ReadoutNeuromuscular Blocking Agents — Respiratory Distress Syndrome, Adult

Aug 31, 2026

UTHRPhase 2 ReadoutCeralasertib — Gynaecological Cancers

Q3 2026

UTHRPhase 2 ReadoutSemaglutide — Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFp EF), Obesity

Q3 2026

UTHRPhase 2 ReadoutAspirin — Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2

Q3 2026

CORTPhase 2 ReadoutRelacorilant 150 mg once daily (QD) — Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms

Q3 2026

IMVTPhase 3 ReadoutBatoclimab — Thyroid Eye Disease

Q3 2026

VSTMPhase 2 Readoutavutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel — KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer

Aug 31, 2026

ABBVPhase 3 ReadoutUpadacitinib 15mg Dose — Atopic Dermatitis

Q3 2026

RCUSPhase 2 ReadoutDomvanalimab — Head and Neck Squamous Cell Carcinoma

Q3 2026

KODPhase 3 ReadoutTarcocimab tedromer — Wet Age-related Macular Degeneration

Q3 2026

RNAPhase 3 ReadoutAOC 1001 (del-desiran) — DM1, Myotonic Dystrophy, Myotonic Dystrophy 1

Q3 2026

RGNXPhase 2 ReadoutRanibizumab — Neovascular Age-Related Macular Degeneration (n AMD)

Q3 2026

GPCRPhase 2 Readoutaleniglipron or placebo — Obesity, Overweight, or Chronic Weight Management

Q3 2026

JAZZPhase 3 ReadoutDordaviprone (ONC201) — H3 K27M, Glioma

Q3 2026

ACRSPhase 2 ReadoutAti-045 — Atopic Dermatitis, Atopic, Dermatitis

Q3 2026

ABBVPhase 2 ReadoutRanibizumab — Neovascular Age-Related Macular Degeneration (n AMD)

Q3 2026

XENEPhase 3 ReadoutAzetukalner — Major Depressive Disorder

Q3 2026

PEPGPhase 2 ReadoutPgn-Edodm1 — Myotonic Dystrophy 1

Q3 2026

BNTXPhase 2 ReadoutPm8002 — CRC (Colorectal Cancer)

Q3 2026

MIRMPhase 3 ReadoutBrelovitug 300 mg — Chronic Hepatitis D Infection

Q3 2026

MPLTPhase 2 ReadoutPlacebo — Schizophrenia

Q3 2026

HELPPhase 3 ReadoutCyb003 — Major Depressive Disorder

Q3 2026

ANROPhase 2 ReadoutAlto-100 — Bipolar Disorder I or II With a Major Depressive Episode

Q3 2026

ENSCWPhase 3 ReadoutPF614 capsule — Postoperative Pain, Acute

Q3 2026

EYPTPhase 3 ReadoutEyp-1901 — Wet Age Related Macular Degeneration, w AMD

Q3 2026

PFEPhase 2 ReadoutTalazoparib — Breast Cancer

Aug 31, 2026

September 2026

INCYPhase 3 ReadoutTafasitamab — Diffuse Large B-cell Lymphoma

Sep 1, 2026

UTHRPhase 2 ReadoutSildenafil — Scleroderma, Mildly Elevated Pulmonary Pressures

Sep 1, 2026

EXELPhase 2 ReadoutCabozantinib 80 MG — RCC, Renal Cell Carcinoma

Sep 1, 2026

PFEPhase 2 ReadoutPalbociclib — Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases

Sep 1, 2026

PFEPhase 2 ReadoutArv-471 — Breast Cancer

Sep 1, 2026

PFEPhase 2 ReadoutPf-07868489 — Pulmonary Arterial Hypertension

Sep 2, 2026

CORTPhase 2 ReadoutMifepristone 1200 mg daily — Treatment-resistant PTSD

Sep 15, 2026

SMMTPhase 2 ReadoutHyperbaric Oxygen Therapy — TBI Traumatic Brain Injury, PTSD - Post Traumatic Stress Disorder, Post Concussive Syndrome

Sep 15, 2026

DSGNPhase 3 ReadoutTopotecan - usual — Sclc

Sep 18, 2026

BEIGFPhase 2 ReadoutSonrotoclax — Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

Sep 22, 2026

PFEPhase 2 ReadoutPf-07220060 — Liposarcoma, Prostate Cancer, Breast Neoplasms

Sep 23, 2026

BIIBPhase 3 ReadoutLitifilimab — Lupus Erythematosus, Systemic

Sep 27, 2026

INCYPhase 2 ReadoutInc.b099280 — Cutaneous Squamous Cell Carcinoma

Sep 28, 2026

UTHRPhase 2 ReadoutMesenchymal Stromal Cells — Corneal Ulcer

Sep 28, 2026

UTHRPhase 2 ReadoutBXCL501 (dexmedetomidine HCl) — Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder

Sep 29, 2026

INCYPhase 2 ReadoutRetifanlimab — Soft Tissue Sarcoma, Sarcoma, Soft Tissue, Sarcoma

Sep 29, 2026

AMGNPhase 3 ReadoutPrednisone — Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma

Sep 30, 2026

UTHRPhase 3 ReadoutStandard of Care PO (oral) antibiotics — Infections, Infected Wound, Nonunion of Fracture

Q3 2026

BIIBPhase 3 ReadoutLitifilimab — Lupus Erythematosus, Systemic

Sep 30, 2026

INCYPhase 3 ReadoutPrednisone — Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma

Sep 30, 2026

UTHRPhase 2 ReadoutBo Nt A — Traumatic Brain Injury

Sep 30, 2026

UTHRPhase 2 ReadoutUnited Therapeutics Corporation — Breast Cancer Recurrent

Sep 30, 2026

MAZEPhase 2 ReadoutMze829 — Proteinuric Kidney Disease

Q3 2026

UTHRPhase 3 ReadoutStandard of care — Post Operative Surgical Site Infection

Sep 30, 2026

ARGXPhase 3 ReadoutEmpasiprubart — Multifocal Motor Neuropathy (MMN), MMN

Q3 2026

CORTPhase 2 ReadoutMiricorilant (Cohort A) — Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)

Q3 2026

CORTPhase 2 ReadoutNenocorilant 200 mg — Neoplasms

Q3 2026

CORTPhase 2 ReadoutDazucorilant 300 mg — Amyotrophic Lateral Sclerosis

Q3 2026

ARGXPhase 3 ReadoutEfgartigimod PH20 SC — Generalized Myasthenia Gravis

Sep 30, 2026

GKOSPhase 2 ReadoutGLK-321 low dose BID — Demodex Blepharitis

Q3 2026

WVEPhase 2 ReadoutWve-006 — Alpha-1 Antitrypsin Deficiency

Q3 2026

IRONPhase 2 ReadoutDisc-0974 — Myelofibrosis; Anemia, Anemia, Myelofibrosis

Q3 2026

VERAPhase 2 ReadoutAtacicept — Ig A Nephropathy (Ig AN), Berger Disease

Q3 2026

DSGNPhase 2 ReadoutDt-168 — Fuchs Endothelial Corneal Dystrophy, Fuchs

Q3 2026

ALKSPhase 3 ReadoutOlz/Sam — Schizophrenia, Bipolar I Disorder

Q3 2026

TPTXPhase 2 ReadoutOral repotrectinib (TPX-0005) — Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma

Sep 30, 2026

CERSPhase 2 ReadoutCerus Corporation — Sickle Cell Disease

Sep 30, 2026

ORICPhase 2 ReadoutOric-114 — Solid Tumors

Q3 2026

EWTXPhase 2 ReadoutSevasemten 10 mg — Becker Muscular Dystrophy

Q3 2026

VTVTPhase 3 ReadoutCadisegliatin 800 mg QD — Diabetes Mellitus, Type 1

Q3 2026

BBNXPhase 3 ReadoutBeta Bionics, Inc. — Cystic Fibrosis-related Diabetes

Sep 30, 2026

SVAPhase 3 ReadoutSinovac rabies vaccine — Rabies (Healthy Volunteers)

Sep 30, 2026

PFEPhase 2 ReadoutAvelumab — Breast Cancer

Sep 30, 2026

SVAPhase 2 ReadoutSinovac PCV24 — Pneumococcal Infectious Disease

Q3 2026

PFEPhase 2 ReadoutIpatasertib 300mg — Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer

Q3 2026

PFEPhase 3 ReadoutAvelumab — Advanced Malignancies, NSCLC, Ovarian Cancer

Sep 30, 2026

October 2026

UTHRPhase 2 ReadoutEvolocumab — Metastatic Renal Cell Carcinoma

Oct 1, 2026

ARGXPhase 3 Readoutefgartigimod PH20 SC — Primary Immune Thrombocytopenia

Oct 1, 2026

IOVAPhase 2 ReadoutE7 TCR-T cells — HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy

Oct 1, 2026

PFEPhase 2 ReadoutAtezolizumab - 28 Day Cycle — Endometrial Cancer

Oct 1, 2026

PFEPhase 2 ReadoutTalazoparib — Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma

Oct 1, 2026

PFEPhase 2 ReadoutSasanlimab — Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma

Oct 1, 2026

Never miss a binary event

Get catalyst alerts, PDUFA dates, and readout results in a free Monday brief.

Recent Outcomes

Last 7 days
INCYPhase 3 ReadoutPositiveRetifanlimab

Mar 29, 2026

AMGNPhase 3 ReadoutPositiveAmg 510

Mar 29, 2026

AMGNPhase 3 ReadoutPositiveInebilizumab

Mar 29, 2026

ALNYPhase 3 ReadoutPositiveVutrisiran

Mar 29, 2026

Get catalyst alerts for your watchlist

Add tickers to your watchlist and get notified when catalysts are approaching or when outcomes are announced.

Start 7-Day Free Trial